Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Norethindrone is a synthetic oral progestin (progestogen) used primarily for contraception (as a "mini-pill" or progestin-only pill), treatment of endometriosis, secondary amenorrhea (absence of menstrual periods in women who have previously menstruated), and abnormal uterine bleeding due to hormonal imbalance. It works by binding to progesterone receptors and exerting effects similar to endogenous progesterone but with higher potency. Its mechanisms include suppression of ovulation in some users by inhibiting pituitary gonadotropins (luteinizing hormone (LH) and follicle-stimulating hormone (FSH)), thickening cervical mucus to inhibit sperm penetration, slowing ovum transport through the fallopian tubes, and altering the endometrial lining to prevent implantation. Norethindrone is also used as part of hormone replacement therapy for menopausal symptoms[1][2][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on norethindrone.